April 11, 2005

Revlimid Delays Multiple Myeloma

Celgene Corp. on Monday said initial results from two pivotal-stage trials show that its blood cancer drug Revlimid in combination with chemotherapy significantly delays progression of multiple myeloma in relapsed patients. (Reuters)

Talk about this story

Remember Me?

Related Stories

More News Topics:
Breast Cancer      Alternative Medicine      Infectious Disease       Eating Disorders       Sleep      Orthopedic      Allergies      Neurological Disorders      Chronic Pain       Senior Health       Heart Health      Mental Health       Autoimmune Disorders       Women's Health
All content published on HealthDiaries.com is provided for informational and educational purposes only. HealthDiaries.com does not provide medical advice, diagnosis or treatment. The site and its services are not a substitute for professional medical advice and treatment. Always seek the advice of your doctor before making any changes to your health routine or treatment.

Copyright © 2004-2005 HealthDiaries.com. All rights reserved.